VivoSim Labs, INC.

VivoSim Labs, Inc., formerly Organovo Holdings, Inc., is a pharmaceutical and biotechnology services company that tests drugs and drug candidates using three-dimensional (3D) human tissue models of the liver and intestine. The company provides liver and intestinal toxicology insights to partners using its new approach methodologies (NAM) models. VivoSim Labs also offers custom services in investigational toxicology, drug mechanism of action elucidation, and other applications of these complex human tissue models. Prior to March 2025, the company was a clinical stage biotechnology company focused on developing FXR314 for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease. In March 2025, VivoSim Labs sold its FXR program for $10.0 million, with $9.0 million paid at closing and $1.0 million held in escrow for 15 months. Future milestones of up to $50.0 million in aggregate are contingent on FXR314 achieving key development, regulatory, and commercial milestones. Effective April 24, 2025, the company changed its name to VivoSim Labs, Inc. to reflect its new business model, which utilizes its intestinal and liver toxicology models, expertise, and intellectual property portfolio for 3D bioprinting.